HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.

Abstract
To date, 13 studies have provided data on the risk of venous thromboembolism associated with combined oral contraceptives containing drospirenone or the norelgestromin-containing contraceptive patch. The studies varied in their conclusions about whether these methods are associated with higher risks than combined oral contraceptives containing other progestins: the primary reported measures of association (adjusted odds ratios, incidence rate ratios, or hazard ratios) ranged from 0.9 to 3.3. All of the studies had weaknesses in population selection, data validity or completeness, or analysis that may have led to biased or spurious findings. Venous thromboembolism is rare; if the contraceptive methods of interest do confer a higher risk of thromboembolism, only an additional 5-10 per 10,000 users per year would be affected. The important message for patients, clinicians, and policy makers is that the benefits of all contraceptive methods markedly outweigh their risks, primarily because they prevent pregnancy, an inherently hazardous condition. Product labels for hormonal contraceptives should emphasize their substantial health benefits and established safety.
AuthorsElizabeth G Raymond, Anne E Burke, Eve Espey
JournalObstetrics and gynecology (Obstet Gynecol) Vol. 119 Issue 5 Pg. 1039-44 (May 2012) ISSN: 1873-233X [Electronic] United States
PMID22525916 (Publication Type: Editorial)
Chemical References
  • Androstenes
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Drug Combinations
  • Ortho Evra
  • drospirenone and ethinyl estradiol combination
  • Norgestrel
  • Ethinyl Estradiol
Topics
  • Androstenes (adverse effects)
  • Contraceptives, Oral, Combined (adverse effects)
  • Contraceptives, Oral, Hormonal (adverse effects)
  • Drug Combinations
  • Drug Labeling
  • Ethinyl Estradiol (adverse effects)
  • Female
  • Humans
  • Norgestrel (adverse effects, analogs & derivatives)
  • Risk Assessment
  • Venous Thromboembolism (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: